UBT-251

Tier C — Watch / trade

UBT-251

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：GLP1R, GCGR, GIPR

Indications (approved)：Obesity, Obstructive sleep apnoea syndrome, Type 2 diabetes, Overweight, Non-alcoholic steatohepatitis, Chronic renal impairment, Drug-related adverse effects and reactions, Renal impairment

Regional status

Phase II

2026-02-02

Phase II

2026-06-22

China

Phase III

2026-06-15

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of UBT-251?

Approved indications include: Obesity, Obstructive sleep apnoea syndrome, Type 2 diabetes, Overweight, Non-alcoholic steatohepatitis, Chronic renal impairment, Drug-related adverse effects and reactions, Renal impairment.

When does the UBT-251 patent expire?

No public expiry year is available for UBT-251 yet; this page updates once verified.

How do I get a quote for UBT-251 intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29